Same but Not the Same Biosimilar Drugs Combating Diseases Like Pros!

Biosimilars are drug copies sharing the safety, purity, and potency of the reference drugs.  However, they differ in terms of clinically inactive components without any consequential implications. Biosimilars are considerably cost-efficient and reduce the expenditure across healthcare systems. Biosimilars cost up to 30% lesser than their parent product. This affordability allow them to be adopted by various economies for the treatment of various diseases such as rheumatoid arthritis, diabetes mellitus, cancers, lupus, etc.

These drugs are used to treat a number of health problems such as blood hormone deficiency, chronic and autoimmune disorders, growth hormone deficiency, and oncology, among many other applications.

Biosimilar INFLECTRA

Pfizer company entered into an agreement with Celltrion Inc., and Celltrion Healthcare, Co., Ltd., for various potential biosimilars including INFLECTRA. Early April 2016, FDA (Food and Drug Administration) approved Celltrion’s INFLECTRA. This is the first and only biosimilar monoclonal antibody (mAb) therapy.

INFLECTRA is a treatment indicated to reduce the signs and symptoms of adult ulcerative colitis, adult and pediatric Crohn’s disease, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis (RA).

Biosimilar Rubraca

FDA granted an approval for Rubraca (rucaparib) to help in the treatment of advanced ovarian cancer.  The medicine is prescribed for women under two or more chemotherapies and whose tumors have reached a specific gene mutation (BRCA), either acquired (somatic) or inherited (germline).

The next-generation-sequencing (NGS) test detects the presence of the BRCA gene mutation in the patient’s tumor tissues of the ovarian cancer. If one or more mutations are detected, the patient is eligible for the Rubraca treatment.

Market Overview

According to a new report by Grand View Research, Inc., the biosimilars market is anticipated to reach USD 41.7 billion by 2024. Cost –effectiveness of these drugs and the encumbrance to reduce expenditure across healthcare systems globally is predicted to drive the market.

Competitive Insight

Abbvie, Inc.; Roche Diagnostics; Sandoz, Inc.; and Teva Pharmaceutical Industries Ltd. are some of the key players of the biosimilars market.

In-Depth research report on biosimilars market:

http://www.grandviewresearch.com/industry-analysis/biosimilars-market